Article
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
10 Jul 2019
Abstract excerpt
Abstract The oncogenic role ERBB2 amplification is well established in breast and gastric cancers. This has led to the development of a well-known portfolio of monoclonal antibodies and kinase inhibitors targeting the ERBB2 kinase. More recently, activating mutations in the ERBB2 gene have been increasingly reported in multiple solid cancers and were shown to play an oncogenic role similar to that of ERBB2...
Topics
Join the communities discussing this publication.